Tolero Pharmaceuticals Receives FDA Orphan Drug Designation For Alvocidib For The Treatment Of Acute Myeloid Leukemia
4/23/2014 9:33:22 AM
SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for Alvocidib for the treatment of patients with acute myeloid leukemia (AML). Alvocidib is being tested in patients with intermediate or high-risk AML, which is determined by a profile of clinical, cytogenetic and molecular features, and typically, individuals with this profile have a poor prognosis due to limited treatment options.
Help employers find you! Check out all the jobs and post your resume.
comments powered by